We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Last week, the Supreme Court granted certiorari to resolve a relatively new Circuit split over a pharmaceutical company's duty to disclose negative information it receives about its products
